These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2664888)

  • 21. The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey.
    Irwin I; DeLanney LE; Forno LS; Finnegan KT; Di Monte DA; Langston JW
    Brain Res; 1990 Oct; 531(1-2):242-52. PubMed ID: 1981162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.
    Murray AM; Weihmueller FB; Marshall JF; Hurtig HI; Gottleib GL; Joyce JN
    Ann Neurol; 1995 Mar; 37(3):300-12. PubMed ID: 7695230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease.
    Ryoo HL; Pierrotti D; Joyce JN
    Mov Disord; 1998 Sep; 13(5):788-97. PubMed ID: 9756147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
    Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
    Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography.
    Robertson RG; Clarke CA; Boyce S; Sambrook MA; Crossman AR
    Brain Res; 1990 Oct; 531(1-2):95-104. PubMed ID: 2289139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imaging in Parkinson's disease: the role of monoamines in behavior.
    Brooks DJ; Piccini P
    Biol Psychiatry; 2006 May; 59(10):908-18. PubMed ID: 16581032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.
    Kish SJ; Tong J; Hornykiewicz O; Rajput A; Chang LJ; Guttman M; Furukawa Y
    Brain; 2008 Jan; 131(Pt 1):120-31. PubMed ID: 17956909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.
    Brooks DJ; Salmon EP; Mathias CJ; Quinn N; Leenders KL; Bannister R; Marsden CD; Frackowiak RS
    Brain; 1990 Oct; 113 ( Pt 5)():1539-52. PubMed ID: 2123119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biochemical aspects of Parkinson's disease.
    Hornykiewicz O
    Neurology; 1998 Aug; 51(2 Suppl 2):S2-9. PubMed ID: 9711973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys.
    Schneider JS
    Brain Res; 1990 Nov; 534(1-2):25-36. PubMed ID: 2073585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
    Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
    Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
    Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
    Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
    Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contrasting tissue factors predict heterogeneous striatal dopamine neurotoxicity after MPTP or methamphetamine treatment.
    Marshall JF; Navarrete RJ
    Brain Res; 1990 Nov; 534(1-2):348-51. PubMed ID: 2073599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
    Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
    Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L; Frohna PA; Joyce JN; Schneider JS
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons.
    Hantraye P; Varastet M; Peschanski M; Riche D; Cesaro P; Willer JC; Maziere M
    Neuroscience; 1993 Mar; 53(1):169-78. PubMed ID: 8469305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study.
    Nimura T; Yamaguchi K; Ando T; Shibuya S; Oikawa T; Nakagawa A; Shirane R; Itoh M; Tominaga T
    J Neurosurg; 2005 Dec; 103(6):968-73. PubMed ID: 16381182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine.
    Sindhu KM; Banerjee R; Senthilkumar KS; Saravanan KS; Raju BC; Rao JM; Mohanakumar KP
    Pharmacol Biochem Behav; 2006 Jun; 84(2):321-9. PubMed ID: 16820197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET.
    Nurmi E; Bergman J; Eskola O; Solin O; Vahlberg T; Sonninen P; Rinne JO
    Synapse; 2003 Jun; 48(3):109-15. PubMed ID: 12645035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.